Safety and immunogenicity of inactivated poliovirus vaccine when given with measles-rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia

• Main Authors: Dr. Ed Clarke, MBChB (Author), Yauba Saidu, MD (Author), Jane U Adetifa, MD (Author), Ikechukwu Adigweme, MBBS (Author), Mariama Badjie Hydara, MBBS (Author), Adedapo O Bashorun, MBBS (Author), Ngozi Moneke-Anyanwoke, MBBS (Author), Ama Umesi, MBBS (Author), Elishia Roberts, BSc (Author), Pa Modou Cham, BSc (Author), Michael E Okoye, MBBS (Author), Kevin E Brown, MBBS (Author), Prof. Matthias Niedrig, PhD (Author), Panchali Roy Chowdhury, MSc (Author), Ralf Clemens, MD (Author), Ananda S Bandyopadhyay, MBBS (Author), Jenny Mueller, MD (Author), David J Jeffries, PhD (Author), Prof. Beate Kampmann, MD (Author)
• Format: Book
• Published: Elsevier, 2016-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: The introduction of the inactivated poliovirus vaccine (IPV) represents a crucial step in the polio eradication endgame. This trial examined the safety and immunogenicity of IPV given alongside the measles-rubella and yellow fever vaccines at 9 months and when given as a full or fraction...